V. Mathrudev

发表

Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once‐a‐week versus once‐every‐3‐weeks cisplatin

A. Bhattacharjee, K. Prabhash, V. Noronha, 2022, Cancer Medicine.

Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone - Additional data from a phase 3 trial.

A. Bhattacharjee, K. Prabhash, V. Noronha, 2021, Oral Oncology.

Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV-negative oropharyngeal cancer

A. Mahajan, P. Pai, A. Bhattacharjee, 2019, Annals of Oncology.

Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.

S. Kannan, P. Pai, A. Bhattacharjee, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation.

P. Pai, A. Bhattacharjee, S. Nair, 2022, Oral oncology.

Post hoc analysis of a randomized controlled trial comparing concurrent chemoradiation with cisplatin versus nimotuzumab-cisplatin, focusing on acute oral mucositis

K. Prabhash, V. Noronha, V. Patil, 2021, Journal of the Egyptian National Cancer Institute.

Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation

P. Chaturvedi, A. Mahajan, P. Pai, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer

P. Chaturvedi, S. Kannan, A. Mahajan, 2019, Cancer.

Audit of screen failure in 15 randomised studies from a low and middle-income country

K. Prabhash, V. Noronha, V. Patil, 2022, Ecancermedicalscience.

Metronomic adjuvant chemotherapy evaluation in locally advanced head and neck cancers post radical chemoradiation – a randomised trial

A. Bhattacharjee, K. Prabhash, V. Noronha, 2023, The Lancet regional health. Southeast Asia.

865MO RMAC study: A randomized study evaluating the efficacy of metronomic adjuvant chemotherapy in patients with recurrent head and neck cancers post salvage surgery, not eligible for re-irradiation

A. Bhattacharjee, K. Prabhash, V. Noronha, 2021, Annals of Oncology.

Lymphopenia during chemoradiation—foe or friend

K. Prabhash, V. Noronha, V. Patil, 2020, Ecancermedicalscience.

Weight loss and its impact on outcome in head and cancer patients during chemo-radiation.

K. Prabhash, V. Noronha, V. Patil, 2021, Oral Oncology.

Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer.

K. Prabhash, V. Noronha, S. Laskar, 2024, European journal of cancer.

Incidence and Outcome of Second Malignancy in Primary Treated Head and Neck Cancer.

K. Prabhash, V. Noronha, A. Joshi, 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

Impact of COVID-19 on oncology clinical trials: A “novel“ challenge

S. Goud, S. More, V. Mathrudev, 2020 .